Brokerages expect that Jounce Therapeutics, Inc. (NASDAQ:JNCE) will report $20.00 million in sales for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Jounce Therapeutics’ earnings. The firm is expected to report its next quarterly earnings report on Wednesday, November 8th.

On average, analysts expect that Jounce Therapeutics will report full-year sales of $20.00 million for the current fiscal year, with estimates ranging from $80.58 million to $81.00 million. For the next year, analysts anticipate that the business will post sales of $129.86 million per share, with estimates ranging from $80.58 million to $206.00 million. Zacks’ sales calculations are a mean average based on a survey of research firms that follow Jounce Therapeutics.

Jounce Therapeutics (NASDAQ:JNCE) last released its earnings results on Wednesday, August 9th. The company reported ($0.11) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.15) by $0.04. The business had revenue of $20.29 million during the quarter, compared to analyst estimates of $19.94 million. During the same quarter in the previous year, the company posted ($7.23) earnings per share.

JNCE has been the topic of a number of research reports. Zacks Investment Research raised shares of Jounce Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective on the stock in a report on Friday, August 11th. Robert W. Baird reissued a “buy” rating and issued a $30.00 price objective on shares of Jounce Therapeutics in a report on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $23.67.

Jounce Therapeutics (NASDAQ JNCE) opened at $15.04 on Friday.

COPYRIGHT VIOLATION WARNING: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was copied illegally and reposted in violation of international copyright laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/11/04/jounce-therapeutics-inc-jnce-expected-to-post-quarterly-sales-of-20-00-million.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Teachers Advisors LLC raised its stake in Jounce Therapeutics by 26.4% during the 2nd quarter. Teachers Advisors LLC now owns 11,231 shares of the company’s stock worth $158,000 after acquiring an additional 2,347 shares during the period. Strs Ohio raised its stake in Jounce Therapeutics by 10.7% during the 3rd quarter. Strs Ohio now owns 41,300 shares of the company’s stock worth $643,000 after acquiring an additional 4,000 shares during the period. Nationwide Fund Advisors raised its stake in Jounce Therapeutics by 203.3% during the 2nd quarter. Nationwide Fund Advisors now owns 11,946 shares of the company’s stock worth $168,000 after acquiring an additional 8,007 shares during the period. Bank of New York Mellon Corp raised its stake in Jounce Therapeutics by 46.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 25,574 shares of the company’s stock worth $359,000 after acquiring an additional 8,063 shares during the period. Finally, Teachers Retirement System of The State of Kentucky raised its stake in Jounce Therapeutics by 180.0% during the 2nd quarter. Teachers Retirement System of The State of Kentucky now owns 12,600 shares of the company’s stock worth $177,000 after acquiring an additional 8,100 shares during the period. Institutional investors own 44.11% of the company’s stock.

Jounce Therapeutics Company Profile

Jounce Therapeutics, Inc is a clinical stage immunotherapy company. The Company is engaged in transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients. Through the use of its Translational Science Platform, Jounce first focuses on specific cell types within tumors to prioritize targets, and then identifies related biomarkers designed to match the right therapy to the right patient.

Get a free copy of the Zacks research report on Jounce Therapeutics (JNCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Jounce Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jounce Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.